NVCR - NovoCure: Addressable Market For TTFields Continues To Expand With Mesothelioma Approval
Shares of NovoCure (NVCR) have risen over fivefold since introducing this medical device story to readers in 2016. The stock price is up over 50% since my December update piece suggested investors take advantage of a "solid buying opportunity" caused by flat prescription growth in Q3.
Figure 1: Daily advanced chart (source: Finviz)
Racking Up Another Approval
Today's news was somewhat expected yet welcome nevertheless, as the company announced FDA approval of its NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic, malignant